Osteoarthritis

Cytokine profiling of molecular endotypes of knee osteoarthritis: insights from the IMI-APPROACH cohort

Arthritis Res TherPublished Exploratory cohort study

Authors' conclusion

This study found that the majority of the cytokines exhibited considerable fluctuations over time with no endotype-specific cytokine profiles.

Study context

Population
Knee osteoarthritis (OA) participants from IMI-APPROACH; 15 serum cytokines measured at 6-, 12- and 24-month visits
Participants
277 participants
Exposure
Cytokine levels across three biomarker-based knee OA endotypes: structural damage, low tissue turnover, connective tissue inflammation
  • Inflammatory endotypen = 92
Outcome
Serum IL-1ra, mean change vs other endotypes
Methodological detailssecondary analysis of the IMI-APPROACH cohort, longitudinal, linear mixed-effects models adjusted for patient-specific random effects, age, sex and BMI
  • Secondary analysis of the IMI-APPROACH cohort
  • Longitudinal
  • Linear mixed-effects models adjusted for patient-specific random effects, age, sex and BMI

Main finding

As reported in the abstract

Mean change (95% CI)P value
Inflammatory endotypevs Structural damage endotype12-month visit
36%(19%–54%)
P < 0.001
Inflammatory endotypevs Structural damage endotypemonth 24
40%(22%–59%)
P < 0.001
Inflammatory endotypevs Low tissue turnover endotype24-month visit
21%(10%–31%)
P = 0.047

Observational data: associations, not effects.

Further findings

Highest vs lowest IL-1ra quartile within inflammatory endotype (n = 23): BMI and WOMAC function

Higher BMI in highest IL-1ra quartile
P = 0.035, Mann-Whitney U test
Worsened WOMAC function in highest IL-1ra quartile
P = 0.035, Mann-Whitney U test

Original publication

Cytokine profiling of molecular endotypes of knee osteoarthritis: insights from the IMI-APPROACH cohort. Arthritis Res Ther. Published 27 January 2026. doi:10.1186/s13075-026-03742-9

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.